BACKGROUND: Recruitment of circulating cells to the inflamed intestine is modulated by adhesion molecules expressed on the surface of both leucocytes and endothelial cells. AIMS: The objective of this study was to test whether 2'-O-methoxyethyl chimeric antisense oligonucleotides directed against endothelial intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) can downregulate leucocyte-endothelial interactions and thereby attenuate inflammation in rat experimental ileitis. METHODS: Indomethacin (7.5 mg/kg ) was injected subcutaneously into Sprague-Dawley rats 48 and 24 hours prior to intravital microscopy. Animals were treated with either ICAM-1 (ISIS 17470), VCAM-1 (ISIS 18155), or scrambled control antisense oligonucleotides administered subcutaneously or intravenously in parallel with indomethacin. Leucocyte trafficking was observed in ileal submucosal collecting venules. Macroscopic and histological grades of inflammation were measured 48 hours after the first indomethacin application. ICAM-1 and VCAM-1 expression in ileal submucosal venules was detected by immunohistochemistry. RESULTS: Intravenous administration of ICAM-1 oligonucleotides 2 mg/kg (rolling leucocytes 5.7 (2.4)/0.01 mm(2) endothelial surface, adherent leucocytes 0.8 (1.1)) and VCAM-1 oligonucleotides 8 mg/kg (9.2 (4.4), 0.6 (0.8)) significantly reduced leucocyte adhesion compared with diseased controls (27.8 (5.3), 14 (4.4)) in a dose dependent manner whereas subcutaneous treatment did not. Correspondingly, macroscopic and histological inflammation was significantly decreased. ICAM-1 oligonucleotides markedly reduced endothelial ICAM-1 expression while VCAM-1 oligonucleotides clearly diminished endothelial VCAM-1 expression. CONCLUSIONS: Both ICAM-1 and VCAM-1 2'-O-methoxyethyl chimeric antisense oligonucleotides attenuate rat ileitis by downregulation of leucocyte adherence and thus are potential candidates for anti-inflammatory treatment in inflammatory bowel disease.
BACKGROUND: Recruitment of circulating cells to the inflamed intestine is modulated by adhesion molecules expressed on the surface of both leucocytes and endothelial cells. AIMS: The objective of this study was to test whether 2'-O-methoxyethyl chimeric antisense oligonucleotides directed against endothelial intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) can downregulate leucocyte-endothelial interactions and thereby attenuate inflammation in rat experimental ileitis. METHODS:Indomethacin (7.5 mg/kg ) was injected subcutaneously into Sprague-Dawley rats 48 and 24 hours prior to intravital microscopy. Animals were treated with either ICAM-1 (ISIS 17470), VCAM-1 (ISIS 18155), or scrambled control antisense oligonucleotides administered subcutaneously or intravenously in parallel with indomethacin. Leucocyte trafficking was observed in ileal submucosal collecting venules. Macroscopic and histological grades of inflammation were measured 48 hours after the first indomethacin application. ICAM-1 and VCAM-1 expression in ileal submucosal venules was detected by immunohistochemistry. RESULTS: Intravenous administration of ICAM-1oligonucleotides 2 mg/kg (rolling leucocytes 5.7 (2.4)/0.01 mm(2) endothelial surface, adherent leucocytes 0.8 (1.1)) and VCAM-1oligonucleotides 8 mg/kg (9.2 (4.4), 0.6 (0.8)) significantly reduced leucocyte adhesion compared with diseased controls (27.8 (5.3), 14 (4.4)) in a dose dependent manner whereas subcutaneous treatment did not. Correspondingly, macroscopic and histological inflammation was significantly decreased. ICAM-1oligonucleotides markedly reduced endothelial ICAM-1 expression while VCAM-1oligonucleotides clearly diminished endothelial VCAM-1 expression. CONCLUSIONS: Both ICAM-1 and VCAM-12'-O-methoxyethyl chimeric antisense oligonucleotides attenuate ratileitis by downregulation of leucocyte adherence and thus are potential candidates for anti-inflammatory treatment in inflammatory bowel disease.
Authors: C F Krieglstein; J W Salter; W H Cerwinka; J M Russell; G Schuermann; M Bruewer; F S Laroux; M B Grisham; D N Granger Journal: Biochem Biophys Res Commun Date: 2001-03-30 Impact factor: 3.575
Authors: F H Gordon; C W Lai; M I Hamilton; M C Allison; E D Srivastava; M G Fouweather; S Donoghue; C Greenlees; J Subhani; P L Amlot; R E Pounder Journal: Gastroenterology Date: 2001-08 Impact factor: 22.682
Authors: A Soriano; A Salas; A Salas; M Sans; M Gironella; M Elena; D C Anderson; J M Piqué; J Panés Journal: Lab Invest Date: 2000-10 Impact factor: 5.662
Authors: G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro Journal: Gastroenterology Date: 1991-01 Impact factor: 22.682
Authors: Maya V Gulubova; Irena M Manolova; Tatyana I Vlaykova; Margarita Prodanova; Jovcho P Jovchev Journal: Int J Colorectal Dis Date: 2006-11-16 Impact factor: 2.571
Authors: Christoph Anthoni; Rudolf B Mennigen; Emile J M Rijcken; Mike G Laukötter; Hans-Ullrich Spiegel; Norbert Senninger; Guido Schürmann; Christian F Krieglstein Journal: Int J Colorectal Dis Date: 2005-08-09 Impact factor: 2.571
Authors: Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-09-17 Impact factor: 4.052
Authors: H L Zhang; Y J Zheng; Y D Pan; C Xie; H Sun; Y H Zhang; M Y Yuan; B L Song; J F Chen Journal: Mucosal Immunol Date: 2015-07-29 Impact factor: 7.313